Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus
A case report
Jeong Suk Koh, MDa, Sina Oh, BSb, Chaeuk Chung, MD, PhD,*, a, c

Abstract
Background: The co-incidence of systemic lupus erythematosus (SLE) and tuberous sclerosis with pulmonary lymphangioleiomyomatosis (LAM) and renal angiomyolipoma (AML) is rare. In such patients, the rupture of renal AML may result in fatal circumstances, but this may be preventable.

Methods: A 22-year-old Asian woman with SLE was admitted to our hospital with severe left-flank pain. Imaging studies showed the bilateral rupture of multiple renal AMLs.

Results: The patient underwent emergency selective transcatheter embolization (TE) of the left renal artery. After TE and massive hydration, the patient complained of dyspnea and postembolization syndrome with fever. The chest computed tomography (CT) revealed pulmonary LAM, pulmonary edema with bilateral pleural effusions, and pneumonic consolidation. After the emergency procedure, the patient was treated with intravenous administration of antibiotics, diuretics, and nonsteroidal anti-inflammatory drugs for 10 days. The patient recovered favorably and was discharged 20 days after the treatment. She was diagnosed with renal AML and pulmonary LAM along with facial angiofibromas as well as tuberous sclerosis complex (TSC), although she had no TSC1 or TSC2 gene mutations.

Conclusion: Although rare, SLE may coexist with TSC, along with LAM and AML, with a risk of AML rupture. The activation of the mTOR signaling pathway is shared between SLE and TSC. Thus, in patients with SLE, clinicians should consider imaging studies, such as kidney sonography and chest CT, to screen for possible manifestation of AML and LAM.

Abbreviations: AML = angiomyolipoma, CT = computed tomography, LAM = lymphangioleiomyomatosis, LDH = lactate dehydrogenase, mMRC = modified Medical Research Council, mTOR = mammalian target of rapamycin, SLE = systemic lupus erythematosus, TE = transcatheter embolization, TSC = tuberous sclerosis complex

Keywords: angiomyolipoma, lymphangioleiomyomatosis, systemic lupus erythematosus, tuberous sclerosis complex

1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease mediated by autoantibodies and immune complexes. Most of the affected patients (90%) were women of childbearing ages. The factors involved in SLE pathogenesis include genetic background, environmental influences, and epigenetics. Several studies have shown that the mammalian target of rapamycin (mTOR) pathway plays an important role in the pathogenesis of SLE. The mammalian target of rapamycin regulates the growth and metabolism of eukaryotic cells according to signals from growth factors and nutrients and is deeply involved in immune responses. Rapamycin has been shown to expand T regulatory cells, thereby suppressing the activation and proliferation of autoreactive T cells and reducing the activity of SLE.[1,2]

The mTOR pathway is also involved in the pathogenesis of tuberous sclerosis complex (TSC), which results from mutations in the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) gene. Tuberous sclerosis complex is an autosomal...
dominant disease that invades multiple systems, with the most commonly affected organs being the brain, skin, kidneys, eyes, heart, and lungs.\(^{[3]}\) Thus, patients with SLE may be at risk of developing TSC, because both diseases involve the mTOR pathway. Tuberous sclerosis complex is also closely related to pulmonary lymphangioleiomyomatosis (LAM), a rare disease in women characterized by smooth muscle cell infiltration and cystic destruction of the lungs,\(^{[8]}\) and renal angiomyolipoma (AML), a mesenchymal tumor and the most common benign tumor of the kidney. Angiomyolipoma occurs in 30%–60% of patients with LAM and may develop many years before its actual diagnosis.\(^{[4]}\)

### 2. Case presentation

The patient was a 22-year-old Asian woman, and her occupation was student. At the age of 15, she was diagnosed with SLE based on cutaneous manifestations (malar rash), a non-scarring alopecia, Raynaud’s phenomenon, thrombocytopenia, hypocomplementemia, and serological evidence (antinuclear antibody titer, 1:1280 [homogeneous pattern]; anti-dsDNA antibody level, 445.96 IU/mL; and anti-Sm antibody-positive) since 2014. She was treated with prednisolone (2.5 mg/day), hydroxychloroquine (200 mg/day), and methotrexate (4 times/week) with no complications. During treatment, her renal function was normal and she had no serious manifestations of SLE or significant laboratory abnormalities. However, she recently developed angiofibromas (Fig. 1) on her face near her nose, which increased in size.

In October 2021, the patient presented with a fever and severe left flank pain. Her blood pressure was 106/65 mmHg, pulse rate was 118 bpm, respiratory rate 20/min, and body temperature 39.5°C. Imaging revealed multiple bilateral renal cysts (Fig. 2). The patient underwent left renal selective transcatheter embolization (TE) for left AMLs rupture using PVA particle (contour\(^\text{TM}\), Boston Scientific) and microcoils (2mm, Nester). After TE and massive hydration, the patient had no respiratory symptoms (Table 1),\(^{[5]}\) she had no history of seizures or other neurological manifestations, and no TSC1 or TSC2 mutations were found. In addition, no TSC mutations were found in her family members, all without a history of SLE.

### 3. Discussion

The frequency of TSC is between 1/6000 and 1/10,000 live births.\(^{[6]}\) and the simultaneous development of SLE and TSC is presumably even lower.

Our patient was diagnosed with SLE and clinical signs of TSC were detected 7 years later. A literature search revealed one case in which TSC was diagnosed before SLE developed and one case of an SLE patient who later developed TSC clinical symptoms, similar to our patient.\(^{[7,8]}\) TSC and SLE share an mTOR pathway in their pathophysologies. The patient visited our hospital with sudden flank pain. Abdominal CT revealed spontaneous AML rupture with multiple invasions in both kidneys. Therefore, arterial embolization was performed. The patient had no respiratory symptoms at the time of initial diagnosis of SLE. Clinically, patients with LAM can have a variety of symptoms including cough, shortness of breath, fatigue, and/or hemoptysis. Disease progression may be accompanied by effusion, lung collapse, or decreased lung function. After TE and massive hydration, the patient complained of dyspnea and exhibited a newly developed bilateral pleural effusion. As the effusion clearly improved after treatment with diuretics and antibiotics, it may not have been caused by LAM. In the present case, if TSC and AML were diagnosed in advance, renal AML rupture might have been preventable. In rare cases, SLE and TSC can occur simultaneously, and LAM and AML screening should be performed when treating SLE patients.

T cells in SLE are associated with disease manifestation and the mTOR pathway is involved in T cell differentiation and function. Rapamycin inhibits the mTOR pathway by increasing the number of regulatory T cells and the production of IL-2, a cytokine essential for regulatory T cells.\(^{[9]}\) Activation of mTOR is thought to be a major cause of TSC and is associated with mutations in TSC1 and TSC2, thus implying a relationship...
Figure 2. Abdominal computed tomography scan. (A) Axial CT image showing bilateral renal AMLs rupture with an intra-hemorrhagic component. (B) Coronal CT scan demonstrating AML rupture in the left kidney. CT = computed tomography, AML = angiomyolipoma.

Figure 3. Chest images. (A) Chest X-ray showing bilateral pleural effusion after left renal selective TE. (B) Following treatment with diuretics and antibiotics, the patient’s chest X-ray findings markedly improved. (C) The mediastinal setting of the chest CT shows pleural effusion in both lungs. (D) The lung setting of the chest CT demonstrates multiple cystic lesions of the lung parenchyma. TE = transcatheter embolization, CT = computed tomography.
In our patient, although a gene mutation was not identified, the clinical manifestations that meet the diagnostic criteria for TSC. Therefore, it is recommended that gene testing be conducted in patients with SLE who show any manifestations suggestive of TSC, even if a specific gene mutation is not identified. This is because some patients with SLE may have variants in the TSC1 or TSC2 genes that are not detectable by standard genetic testing.

There is evidence to suggest that SLE and TSC may share some degree of overlap in terms of the underlying pathogenic mechanisms. Both diseases rely on mTOR signaling, which may account for their coexistence. Although such cases are rare, clinicians should consider imaging tests to screen for LAM and AML when treating SLE patients.

In conclusion, this report describes the coexistence of TSC with LAM and renal AML rupture in a patient with SLE. Both SLE and TSC rely on mTOR signaling, which may account for their coexistence. Although such cases are rare, clinicians should consider imaging tests to screen for LAM and AML when treating SLE patients.

**Author contributions**

JSK and SO wrote the manuscript. CC revised the manuscript and provided guidance. All the authors have read and approved the final manuscript.

**Investigation:** Jeong Suk Koh, Sina Oh, Chaeuk Chung.

**Supervision:** Chaeuk Chung.

**Writing-original draft:** Jeong Suk Koh, Sina Oh.

**Writing-review & editing:** Chaeuk Chung.

**References**

[1] Fernandez D, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discovery Med. 2010;9:173–8.

[2] Islam MP, Roach ES. Chapter 6 - Tuberous sclerosis complex. In: Islam MP, Roach ES, (eds). Handbook of clinical neurology. Vol 132: Elsevier. 2015:97–109.

[3] McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133:507–16.

[4] De Pauw RA, Boelaert JR, Haenebalcke CW, Matthys EG, Schurgers MS, De Vriese AS. Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis. Am J Kidney Disease. 2003;41:877–83.

[5] Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;143:50–66.

[6] Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:243–54.

[7] Carrasco Cubero C, Bejarano Moguel V, Fernández Gil M, Álvarez Vega JL. Coincidence of tuberous sclerosis and systemic lupus erythematosus—a case report. Reumatologia Clinica. 2016;12:219–22.

[8] Singh N, Birkenbach M, Caza T, Perl A, Cohen PL. Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol. 2013;19:134–7.

[9] He J, Ma J, Ren B, Liu A. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway. Semin Arthritis Rheum. 2020;50:314–20.

[10] MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015;17:1530–9.